Vicriviroc, also known as SCH 417690 and SCH-D, is a potent, orally active and selective CCR5 entry inhibitor of HIV-1. Vicriviroc is effective at nanomolar concentrations, it can be administered once daily. Vicriviroc binds to a small hydrophobic pocket between the transmembrane helices near the extracellular surface of the CCR5 receptor. Binding to this pocket induces a conformational change of the extracellular segment of CCR5 and prevents binding of gp120 to the target cell, consequently preventing the virus from entering the target cell at all.
中文名称:
(4,6-二甲基-5-嘧啶基)[4-[(3S)-4-[(1R)-2-甲氧基-1-[4-(三氟甲基)苯基]乙基]-3-甲基-1-哌嗪基]-4-甲基哌啶-1-基]甲酮
物化属性:
密度:1.196
沸点:608.1°Cat760mmHg
折射率:1.541
闪光点:321.5°C